Major histocompatibility complex control of immunity elicited by genetically engineered Eimeria tenella (Apicomplexa) antigen in chickens.

1989 ◽  
Vol 57 (3) ◽  
pp. 701-705 ◽  
Author(s):  
R A Clare ◽  
H D Danforth
Keyword(s):  
Major Histocompatibility Complex ◽  
Eimeria Tenella ◽  
Genetically Engineered ◽  
Major Histocompatibility ◽  
Complex Control ◽  
Histocompatibility Complex

scholarly journals Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.

1995 ◽  
Vol 181 (2) ◽  
pp. 619-629 ◽  
Author(s):  
S Baskar ◽  
L Glimcher ◽  
N Nabavi ◽  
R T Jones ◽  
S Ostrand-Rosenberg
Keyword(s):  
Major Histocompatibility Complex ◽  
Tumor Cells ◽  
Mhc Class Ii ◽  
Class Ii ◽  
Genetically Engineered ◽  
Tumor Rejection ◽  
Major Histocompatibility ◽  
Histocompatibility Complex ◽  
Cell Immunity ◽  
Sarcoma Cells

Mice carrying large established major histocompatibility complex (MHC) class 1+ sarcoma tumors can be successfully treated by immunization with genetically engineered sarcoma cells transfected with syngeneic MHC class II plus B7-1 genes. This approach is significantly more effective than previously described strategies using cytokine- or B7-transduced tumor cells which are only effective against smaller tumor loads, and which cannot mediate regression of longer-term established tumors. The most efficient tumor rejection occurs if both the class II and B7-1 molecules are coexpressed on the same tumor cell. Immunity induced by immunization with class II+B7-1(+)-transfected sarcoma cells involves CD4+ and CD8+ T cells, suggesting that the increased effectiveness of the transfectants is due to their ability to activate both of these T cell populations.

Sign in / Sign up

Export Citation Format

Share Document